BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 26673249)

  • 1. Long-term lamivudine for chronic hepatitis B and cirrhosis: A real-life cohort study.
    Su MH; Lu AL; Li SH; Zhong SH; Wang BJ; Wu XL; Mo YY; Liang P; Liu ZH; Xie R; He LX; Fu WD; Jiang JN
    World J Gastroenterol; 2015 Dec; 21(46):13087-94. PubMed ID: 26673249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telbivudine versus lamivudine and entecavir for treatment-naïve decompensated hepatitis B virus-related cirrhosis.
    Yue-Meng W; Li YH; Wu HM; Yang J; Xu Y; Yang LH; Yang JH
    Clin Exp Med; 2017 May; 17(2):233-241. PubMed ID: 27094312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.
    Yang DH; Xie YJ; Zhao NF; Pan HY; Li MW; Huang HJ
    World J Gastroenterol; 2015 Mar; 21(9):2746-53. PubMed ID: 25759545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognosis of hepatitis B-related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents.
    Kim CH; Um SH; Seo YS; Jung JY; Kim JD; Yim HJ; Keum B; Kim YS; Jeen YT; Lee HS; Chun HJ; Kim CD; Ryu HS
    J Gastroenterol Hepatol; 2012 Oct; 27(10):1589-95. PubMed ID: 22554121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
    Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
    J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome of lamivudine-resistant chronic hepatitis B patients with compensated cirrhosis under adefovir salvage treatment. Importance of HCC surveillance.
    Elefsiniotis I; Buti M; Jardi R; Vezali E; Esteban R
    Eur J Intern Med; 2009 Sep; 20(5):478-81. PubMed ID: 19712848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
    Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
    Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histological outcome for chronic hepatitis B patients treated with entecavir vs lamivudine-based therapy.
    Wang JL; Du XF; Chen SL; Yu YQ; Wang J; Hu XQ; Shao LY; Chen JZ; Weng XH; Zhang WH
    World J Gastroenterol; 2015 Aug; 21(32):9598-606. PubMed ID: 26327767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response-guided treatment of cirrhotic chronic hepatitis B patients: multicenter prospective study.
    Gu EL; Yu YQ; Wang JL; Ji YY; Ma XY; Xie Q; Pan HY; Wu SM; Li J; Chen CW; Xu XW; Wang YE; Yao GB; Wang H; Zhang WH
    World J Gastroenterol; 2015 Jan; 21(2):653-60. PubMed ID: 25605989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.
    Vassiliadis TG; Giouleme O; Koumerkeridis G; Koumaras H; Tziomalos K; Patsiaoura K; Grammatikos N; Mpoumponaris A; Gkisakis D; Theodoropoulos K; Panderi A; Katsinelos P; Eugenidis N
    J Gastroenterol Hepatol; 2010 Jan; 25(1):54-60. PubMed ID: 19780875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
    Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
    Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral Nucleos(t)ide Analogs Alone After Liver Transplantation in Chronic Hepatitis B With Preexisting rt204 Mutation.
    Fung J; Wong T; Chok K; Chan A; Sin SL; Cheung TT; Dai WC; Ng K; Ng K; Man K; Seto WK; Lai CL; Yuen MF; Lo CM
    Transplantation; 2017 Oct; 101(10):2391-2398. PubMed ID: 28731907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis B.
    Kim HS; Kim BK; Kim SU; Park JY; Kim DY; Song KJ; Park JW; Kim YJ; Baatarkhuu O; Han KH; Ahn SH
    Clin Gastroenterol Hepatol; 2016 Nov; 14(11):1647-1656.e6. PubMed ID: 27305847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.
    Al-Hamoudi W; Elsiesy H; Bendahmash A; Al-Masri N; Ali S; Allam N; Al Sofayan M; Al Bahili H; Al Sebayel M; Broering D; Saab S; Abaalkhail F
    World J Gastroenterol; 2015 Jul; 21(26):8140-7. PubMed ID: 26185387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma.
    Jin YJ; Shim JH; Lee HC; Yoo DJ; Kim KM; Lim YS; Suh DJ
    J Gastroenterol Hepatol; 2011 Sep; 26(9):1380-8. PubMed ID: 21884247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection.
    Hosaka T; Suzuki F; Kobayashi M; Seko Y; Kawamura Y; Sezaki H; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    Hepatology; 2013 Jul; 58(1):98-107. PubMed ID: 23213040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy.
    Jiang XY; Huang B; Huang DP; Wei CS; Zhong WC; Peng DT; Huang FR; Tong GD
    World J Gastroenterol; 2021 Mar; 27(11):1101-1116. PubMed ID: 33776376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long term outcome of antiviral therapy in patients with hepatitis B associated decompensated cirrhosis.
    Ju YC; Jun DW; Choi J; Saeed WK; Lee HY; Oh HW
    World J Gastroenterol; 2018 Oct; 24(40):4606-4614. PubMed ID: 30386110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma.
    Shin HS; Kim SU; Park JY; Kim DY; Han KH; Chon CY; Baatarkhuu O; Ahn SH
    J Gastroenterol Hepatol; 2012 Sep; 27(9):1528-34. PubMed ID: 22497450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On-treatment and off-treatment efficacy of entecavir in a real-life cohort of chronic hepatitis B patients.
    Park CH; Kim HY; Lee SW; Song do S; Song MJ; Kwon JH; You CR; Jang JW; Kim CW; Choi SW; Bae SH; Choi JY; Yoon SK
    Eur J Gastroenterol Hepatol; 2016 Oct; 28(10):1179-87. PubMed ID: 27428552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.